Investment in Eyetech
18 Noviembre 2003 - 4:13AM
UK Regulatory
RNS Number:1811S
Intl. Biotechnology Trust PLC
18 November 2003
18 November 2003
Investment in Eyetech
International Biotechnology Trust plc ("IBT") announces that Eyetech
Pharmaceuticals Inc ("Eyetech") updated its S1 Registration statement on
November 14 2003 with the US Securities and Exchange. In this filing, Eyetech
analysed the results from the first year of the Phase 2/3 pivotal clinical
trials for the use of Macugen in the treatment of wet AMD (age-related macular
degeneration). At 31 August 2003, Eyetech represented 5.86% of IBT's NAV and was
valued at #3.1m.
For further information please contact:
Kate Bingham Tel: 020 7421 7068
Schroder Ventures Life Sciences Advisers (UK) Limited
John Spedding Tel: 020 7658 3206
Schroder Investment Management Limited
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUWARROARAAAA